

## Product Information

# SIGMAFAST™ 3,3'-Diaminobenzidine tablets



Tablet, to prepare 15 mL

**D4418**

## Product Description

Diaminobenzidine (DAB) is used in many applications for visualization of peroxidase activity.<sup>1-6</sup> DAB is the immunohistology substrate of choice, as it produces an intense brown-black stain, which is resistant to alcohol. Slides stained with DAB may be cover-slipped in the traditional manner and stored for future reference.

SIGMAFAST™ 3,3'-Diaminobenzidine tablets have been developed for use in immunohistology as a precipitating substrate for the detection of peroxidase activity:



SIGMAFAST™ DAB tablets require no additional ingredients or procedures to prepare an active substrate solution. One SIGMAFAST™ DAB tablet set (one DAB tablet and one Urea Hydrogen Peroxide tablet) dissolved in 15 mL of ultrapure water provides 15 mL of a ready-to-use substrate solution that contains:

- 3,3'-Diaminobenzidine (DAB): 0.7 mg/mL
- Urea Hydrogen Peroxide (H<sub>2</sub>O<sub>2</sub> equivalence, 0.7 mg/mL): 2.0 mg/mL
- Trizma® buffer: 60 mM

This product has been used to study such systems as viruses,<sup>7</sup> honey bee brain,<sup>8</sup> tissues related to Alzheimer's Disease,<sup>9,10</sup> sow sera,<sup>11</sup> Pertussis toxin samples,<sup>12</sup> cells from cultured mouse embryos,<sup>13</sup> and rat brain samples.<sup>14</sup> Several theses<sup>15-18</sup> and dissertations<sup>19-32</sup> have cited use of product D4418 in their research protocols.

## Storage/Stability

Store the tablets at -20 °C.

## Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

## Components

- 3,3'-Diaminobenzidine (DAB) tablets (Component Number D9417): 5SET (5 tablets) or 50SET (50 tablets)
- Urea Hydrogen Peroxide tablets (Component Number U1380): 5SET (5 tablets) or 50SET (50 tablets)

## Reagents and Equipment Required but Not Provided

- Ultrapure water (17 MΩ•cm or equivalent)
- Pipette capable of delivering 15 mL
- Test tubes

## Additional Optional Materials

- 0.2 µm filter (such as Cat. No. WHA10462701)
- Nickel(II) chloride (NiCl<sub>2</sub>) or Cobalt(II) chloride (CoCl<sub>2</sub>), to prepare 0.3% (w/v) stock solution to enhance tissue stains
- PBS (such as Cat. No. P4417) for washing

## Preparation Instructions

1. Remove the required number of DAB and Urea Hydrogen Peroxide tablets from the freezer.
2. Allow the tablets to reach room temperature.
3. Open DAB tablet package (silver foil) and Urea Hydrogen Peroxide tablet package (gold foil). Drop the tablets into an appropriate container.  
**Do not touch the tablets with your fingers.**

4. Add 15 mL of ultrapure water.
5. Vortex until dissolved.

The SIGMAFAST™ DAB Substrate Solution is now ready for use. For best results, the solution should be used within one hour.

## Procedure

1. Cover the treated tissue section with 0.2-0.5 mL of DAB Substrate Solution.
2. The DAB reaction may occur rapidly. Color development should be carefully monitored during the reaction to prevent overdevelopment and high backgrounds. Reactions may be stopped by gently washing the slide in water or PBS.
3. DAB reactions may be enhanced by the addition of a NiCl<sub>2</sub> or CoCl<sub>2</sub> solution. Add 1.5 mL of 0.3% (w/v) stock solution to 13.5 mL DAB Substrate Solution. The addition of metal salts to DAB changes the color of the precipitate product to black or blue-black.
4. Occasionally the DAB Substrate Solution may be hazy. The haziness may be removed by filtering the solution through a 0.2 µm filter.
5. Tissues stained with SIGMAFAST™ DAB Substrate Solution may be dehydrated with alcohol and mounted with traditional resinous mounting media.

## Troubleshooting

### Background is too high

1. Use a blocking step prior to the application of the primary antibody. Diluted normal serum (10% v/v) from the same species as the secondary antibody generally produces the best results.
2. Block endogenous peroxidase by flooding the slide with a solution of 4 parts methanol and 1 part 3% H<sub>2</sub>O<sub>2</sub> solution.
3. Decrease the staining time.
4. Titer the conjugate to optimize working dilution.

### No color develops or color is too faint

1. Adjust the concentration of the primary antibody.
2. Adjust the concentration of the secondary antibody.
3. Determine if the enzyme conjugate is active.
4. Consider using an amplifying system such as avidin-biotin or peroxidase anti-peroxidase.
5. Increase the staining time.

6. Determine if enzymatic treatment (unmasking) of the antigen is required prior to application of the primary antibody.

## References

1. Nakane, P.K., and Pierce, G.B., Jr., *J. Histochem. Cytochem.*, **14(12)**, 929-931 (1966).
2. Trojanowski, J.Q. *et al.*, *J. Histochem. Cytochem.*, **31**, 1217-1223 (1983).
3. DeJong, A.S.H. *et al.*, *Histochem. J.*, **17(10)**, 1119-1130 (1985).
4. Chu, N.M. *et al.*, *J. Histochem. Cytochem.*, **37(2)**, 257-263 (1989).
5. Merchenthaler, I. *et al.*, "Silver Intensification in Immunocytochemistry", in *Techniques in Immunocytochemistry* (Bullock, G., and Petrusz, P., eds.). Academic Press Ltd. (San Diego, CA), pp. 217-252 (1989).
6. Hsu, S., and Soban, E., *J. Histochem. Cytochem.*, **30(10)**, 1079-1082 (1982).
7. Thullier, P., and Sesardic, D., "Neutralization Tests", in *Antibody Engineering, Volume 1* (2<sup>nd</sup> ed.; R. Kontermann and S. Dübel, eds.). Springer-Verlag (Berlin/Heidelberg), pp. 705-722 (2001).
8. Fahrbach, S.E. *et al.*, *Neurosci. Lett.*, **197(2)**, 145-148 (1995).
9. Hales, C.M. *et al.*, *J. Neuropathol. Exp. Neurol.*, **72(11)**, 1009-1015 (2013).
10. Diner, I. *et al.*, *J. Biol. Chem.*, **289(51)**, 35296-35313 (2014).
11. Grosso, M.C. *et al.*, *Immunología*, **31(4)**, 106-114 (2012).
12. Asokanathan, C. *et al.*, *J. Clin. Exp. Pathol.*, **5(5)**, 1000243 (2015).
13. Dunn, K.J. *et al.*, *Proc. Nat. Acad. Sci. USA*, **97(18)**, 10050-10055 (2000).
14. Shin, J.-W. *et al.*, *J. Comp. Neurol.*, **511(5)**, 628-657 (2008).
15. Lin, Heping, "A study on the midgut hormone and its intermediate target hormones in the queen blow fly *Phormia Regina* (Diptera: Calliphoridae)". University of Massachusetts Amherst, M.S. thesis, p. 19 (2003).
16. Henkel, Matthew A., "Evaluation of Pilo Substrate Specificity Using Normally Non-Glycosylated Proteins in *Pseudomonas Aeruginosa*". Duquesne University, M.Sc. thesis, p. 75 (2009).
17. Lee, Soo Kyung, "Microglial Activation in Mice Overexpressing Human Wildtype Alpha-Synuclein". University of California Los Angeles, M.S. thesis, p. 8 (2012).

**MILLIPORE**  
**SIGMA**

18. Antunes, Inês Curado Batista, "Studying laminins in skeletal muscle development: Regulators of muscle stem cells and synaptic organizers". Universidade de Lisboa, M.Sc. thesis, p. 18 (2017).
19. Clayton, Maureen Elizabeth, "Lipoproteins and Heat Shock Proteins as Measures of Reproductive Physiology in the Soft Shell Clam *Mya arenaria*". Massachusetts Institute of Technology, Ph.D. dissertation, p. 111 (1996).
20. Cross, Stuart, "*In vitro* studies of the enzymes involved in fluorometabolite biosynthesis in *Streptomyces cattleya*". University of St. Andrews, Ph.D. dissertation, p. 206 (2008).
21. Marlatt, Michael William, "Activity- and pharmacology-dependent modulation of adult neurogenesis in relation to Alzheimer's disease". Universiteit van Amsterdam, Ph.D. dissertation, pp. 115, 184 (2012).
22. Qaseem, Asif Shehzad, "Modulation of immune cell functions by human lung surfactant protein SP-D in allergic asthma". Brunel University London, Ph.D. dissertation, p. 67 (2013).
23. Chen, Weihua, "Role of RhoA/ROCK pathway in angiogenesis and their potential values in prostate cancer treatment". Université Paris Descartes, Ph.D. dissertation, p. 74 (2014).
24. Cheng, Chieh-Yang, "Understanding Prostate Cancer Pathogenesis". Cornell University, Ph.D. dissertation, p. 97 (2014).
25. Santiago, Nahir Cortés, "Role of the Ang-Tie2 pathway in the invasive recurrence of GBM following anti-VEGF therapy". University of Texas Health Science Center at Houston, Ph.D. dissertation, p. 19 (2014).
26. Smith, Jacob Matthew, "Role of the Autism-Associated Met Tyrosine Kinase Receptor in Cerebral Cortical Development". University of Maryland Baltimore, Ph.D. dissertation, p. 131 (2014).
27. Aboutalebi, Helia, "Establishing and using the new Tet system to study Parkinson's disease in mice". Universität Hamburg, Ph.D. dissertation, p. 38 (2016).
28. Mischler, Shannon Katie, "The neural mechanisms underlying the perception and production of learned vocalizations in songbirds ". University of Western Ontario, Ph.D. dissertation, pp. 50, 135 (2017).
29. Mustroph, Martina Laetitia, "Effects of Physical Exercise and Exercise-Induced Adult Hippocampal Neurogenesis on Conditioned Place Preference for Cocaine in Mice". University of Illinois Urbana-Champaign, Ph.D. dissertation, pp. 28, 54, 80, 110 (2014).
30. Zawia, Amira Abdulmajid, "Investigating the role of macrophages in pulmonary arterial hypertension using the MacLow mouse model". University of Sheffield Ph.D. dissertation, p. 212 (2018).
31. Gallardo, Christopher, "Investigation of Monoaminergic Neurotransmitter Systems as a Method to Study Alzheimer's Disease-Related Neurodegeneration". University of Minnesota, Ph.D. dissertation, p. 40 (2018).
32. Scully, Erin N., "Behavioural and Neurobiological Perception of Vocal Communication in Songbirds". University of Alberta, Ph.D. dissertation, pp. 43, 59, 60, 78 (2020).

## Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

## Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://SigmaAldrich.com/techservice).

## Standard Warranty

The applicable warranty for the products listed in this publication may be found at [SigmaAldrich.com/terms](https://SigmaAldrich.com/terms).

## Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://SigmaAldrich.com/offices).

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

MilliporeSigma, and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.  
© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

D4418dat Rev 03/22 PCS, RBG, GCY, MAM

